Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Everolimus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    309 result(s) found for: Everolimus. Displaying page 1 of 16.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-023630-24 Sponsor Protocol Number: Ev02 Start Date*: Information not available in EudraCT
    Sponsor Name:GMIHO mbH
    Full Title: Phase II open-label pilot study evaluating the safety and efficacy of Certican ® (everolimus) in the prevention of chronic graft-versus-host disease and late pulmonary complications after allogenei...
    Medical condition: Prevention of chronic graft-versus-host disease and late pulmonary complications after allogeneic hematopoietic stem cell transplantation blood
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10053239 Prophylaxis against graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004707-12 Sponsor Protocol Number: CRAD001C2X01B Start Date*: 2013-05-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center everolimus roll-over protocol for patients who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued...
    Medical condition: Disease corresponding to the Novartis-sponsored study the patient will be transitioning from
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Prematurely Ended) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003065-17 Sponsor Protocol Number: CRAD001Y24135 Start Date*: 2013-05-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally ad...
    Medical condition: Estrogen receptor positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) NL (Completed) PT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-023032-17 Sponsor Protocol Number: CRAD001K24133 Start Date*: 2011-04-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors
    Medical condition: The study will evaluate the safety of everolimus in patients with advanced neuroendocrine tumors of gastrointestinal, lung or pancreatic origin.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) SE (Prematurely Ended) GR (Completed) BE (Completed) DK (Completed) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002258-60 Sponsor Protocol Number: UMCN-ONCO-201302 Start Date*: 2013-08-30
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: prediction of everolimus-induced interstitial lung disease in breast cancer patients; maximizing efficacy by reducing toxicity
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001731-40 Sponsor Protocol Number: UMCN-ONCO-201301 Start Date*: 2013-08-26
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Influence of exceptional patient characteristics on everolimus exposure
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003757-28 Sponsor Protocol Number: CRAD001Y2201 Start Date*: 2013-02-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen r...
    Medical condition: Estrogen receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) SE (Completed) GB (Completed) IE (Completed) DK (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-019398-14 Sponsor Protocol Number: RB02 Start Date*: 2010-10-07
    Sponsor Name:Erasmus Medical Center
    Full Title: IMPROVEMENT OF RENAL FUNCTION BY CONVERSION OF TACROLIMUS TO EVEROLIMUS 3 MONTHS AFTER KIDNEY TRANSPLANTATION
    Medical condition: Kidney Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001099-13 Sponsor Protocol Number: CRAD001K24133E1 Start Date*: 2012-05-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors
    Medical condition: advanced neuroendocrine tumors of gastrointestinal or lung origin
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002531-18 Sponsor Protocol Number: 69HCL16_0062 Start Date*: 2018-10-31
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Topical Everolimus versus placebo for the treatment of facial angiofibromas in patients with tuberous sclerosis complex. A phase II/III, multicentre, randomized, double-blind, placebo-controlled st...
    Medical condition: angiofibromas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002429 Angiofibroma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005461-13 Sponsor Protocol Number: CLEE011X2106 Start Date*: 2013-10-12
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase Ib/II trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with estrogen receptor positive Her2 negative locally advanced or metas...
    Medical condition: estrogen receptor positive, Her2- locally advanced or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-000322-66 Sponsor Protocol Number: CRAD001A2433 Start Date*: 2013-11-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibi...
    Medical condition: Adult kidney transplant recipients.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) SK (Completed) ES (Completed) PT (Completed) AT (Completed) NL (Completed) BE (Completed) GR (Completed) CZ (Completed) SI (Completed) BG (Completed) PL (Completed) HR (Completed) NO (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001473-25 Sponsor Protocol Number: CRAD001A2401 Start Date*: 2005-01-27
    Sponsor Name:Novartis Pharmaceuticals Corporation
    Full Title: A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation.
    Medical condition: Solid Organ Transplant - maintenace phase
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021370-11 Sponsor Protocol Number: CRAD001LDE36T Start Date*: 2010-12-29
    Sponsor Name:iOMEDICO AG
    Full Title: An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy.
    Medical condition: metastatic renal cell carcinoma, second line therapy after failure of one VEGF-TKI targeted therapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000299-40 Sponsor Protocol Number: CRAD001C2121 Start Date*: 2016-05-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg ev...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-009461-33 Sponsor Protocol Number: AV-IT-001 Start Date*: 2009-06-04
    Sponsor Name:AISAR ASSOCIAZIONE ITALIANA PER LO STUDIO DEGLI ANTIMICROBICI E DELLE RESISTENZE
    Full Title: A Phase IIa, Open-Label, Dose-Escalating Study to Evaluate the Safety of AV-951 in Combination with Everolimus in Subjects with Metastatic Renal Cell Carcinoma
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000864-16 Sponsor Protocol Number: CRAD001AIT02 Start Date*: 2005-04-12
    Sponsor Name:NOVARTIS FARMA
    Full Title: Multicenter, randomized, open-label trial to evaluate the safety, tolerability and efficacy of two regimens of Everolimus plus Neoral, given according different blood target levels, in de novo rena...
    Medical condition: Prevention of rejection in adult renal transplant patients in combination with Neoral and corticosteroids
    Disease: Version SOC Term Classification Code Term Level
    6.1 10023439 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020447-13 Sponsor Protocol Number: CRAD001L2404 Start Date*: 2012-08-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multicenter phase II study to examine the efficacy and safety of everolimus as second-line therapy in the treatment of patients with metastatic renal cell carcinoma
    Medical condition: Metastatic Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-004876-10 Sponsor Protocol Number: ASF-EVER.1 Start Date*: 2007-08-06
    Sponsor Name:Department of Ophthalmology at St. Franziskus Hospital
    Full Title: single center study on safety and efficacy of everolimus in patients with endogenous intermediate and posterior uveitis
    Medical condition: Uveitis, specially endogenous interemdiate and posterior uveitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10046851 Uveitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005126-35 Sponsor Protocol Number: GBG86-DESIREE Start Date*: 2015-06-03
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer
    Medical condition: Advance Breast cancer under endocrine treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:41:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA